指南与共识慢性肾脏病血液净化与透析肾移植

ASN肾脏健康指导:心血管-肾脏-代谢综合征

ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.
指南 / 共识 · J Am Soc Nephrol · 2026-09-02

美国肾脏病学会发布肾脏健康指导,针对心血管-肾脏-代谢(CKM)综合征框架在肾病人群中的应用提供实践建议。指导强调eGFR与白蛋白尿的纵向评估、心血管风险预测模型整合,以及SGLT2抑制剂、GLP-1类药物和非甾体盐皮质激素受体拮抗剂等药物的心肾获益。

要点

  • eGFR与白蛋白尿是心血管和肾脏风险评估的基础标志物,需纵向评估。
  • 整合PREVENT方程与KFRE有助于早期识别高危患者并指导治疗强化。
  • SGLT2抑制剂、GLP-1类药物和非甾体MRA具有心血管和肾脏双重获益。

核心结论

  • 在肾脏病实践中采用CKM框架可促进协调的多学科护理,从器官特异性管理转向整体管理,以减少心血管事件、延缓肾病进展并改善以患者为中心的结局。

研究设计与样本

  • 美国肾脏病学会(ASN)发布的肾脏健康指导,为肾内科临床医生提供CKM谱系筛查、风险分层和药物治疗的实践指导。

主要发现

  • 肾病患者在肾病严重程度全谱中动脉粥样硬化心血管事件、心力衰竭、肾衰竭和过早死亡风险显著升高。
  • SGLT2抑制剂、GLP-1为基础的治疗和非甾体盐皮质激素受体拮抗剂联合已确立的RAS抑制剂和降脂治疗,已证明具有心血管和肾脏获益。
  • 在晚期CKD、透析肾衰竭、肾移植受者、年轻和老年个体以及非代谢性肾病(包括肾小球疾病)患者中,应用CKM框架仍存在重要差距。

关键数值与推荐

  • 强调纵向评估估算肾小球滤过率(eGFR)和白蛋白尿作为心血管和肾脏风险的基础标志物,包括心脏生物标志物和影像学的作用。
  • 整合心血管和肾脏风险预测模型,包括美国心脏协会PREVENT方程和肾衰竭风险方程(KFRE),可能支持早期识别高危患者并指导治疗强化。
  • 审查支持CKM治疗序贯和联合方法的证据、不良反应管理策略以及数据有限CKD亚人群的特殊考虑。

临床怎么用

  • 肾内科临床医生应纵向评估eGFR和白蛋白尿,并考虑心脏生物标志物和影像学用于心血管筛查。
  • 可整合PREVENT方程与KFRE等风险预测模型,早期识别高危患者并指导治疗强化。
  • 应采用序贯和联合的CKM药物治疗策略,并管理不良反应,同时关注数据有限亚人群的特殊考虑。

局限性

  • 在晚期CKD、透析、肾移植、年轻和老年个体及非代谢性肾病患者中,应用CKM框架仍存在重要差距。
  • 部分CKD亚人群的数据较为有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: The cardiovascular-kidney-metabolic (CKM) syndrome framework has important implications in the care of people with kidney diseases. Cardiovascular screening is important in people with kidney diseases, but the approach may differ in this high-risk population. Multiple pharmacotherapies for CKM syndrome offer significant cardiovascular and kidney benefits. UNLABELLED: Cardiovascular-kidney-metabolic (CKM) syndrome highlights the interconnected nature of cardiovascular disease, CKD, and metabolic dysfunction and underscores the need for integrated approaches to prevention and treatment. Patients with kidney diseases are at markedly elevated risk for atherosclerotic cardiovascular events, heart failure, kidney failure, and premature mortality across the spectrum of kidney disease severity. Recent advances in therapeutics, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1)-based therapies, and nonsteroidal mineralocorticoid receptor antagonists, alongside established renin-angiotensin system inhibitors and lipid-lowering therapies, have transformed the management of CKM by demonstrating both cardiovascular and kidney benefits. However, important gaps remain in applying the CKM framework to patients with kidney diseases, particularly among individuals with advanced CKD, kidney failure treated with dialysis, kidney transplant recipients, younger and older individuals, and those with nonmetabolic kidney diseases including glomerular disorders. This American Society of Nephrology Kidney Health Guidance provides practical guidance for nephrology clinicians on screening, risk stratification, and pharmacologic management across the CKM spectrum. The guidance emphasizes the importance of longitudinal assessment of estimated glomerular filtration rate and albuminuria as foundational markers of cardiovascular and kidney risk, including the role of cardiac biomarkers and imaging. Integration of cardiovascular and kidney risk prediction models, including the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations and the Kidney Failure Risk Equation (KFRE), may support early identification of high-risk patients and guide treatment intensification. The guidance also reviews evidence supporting sequential and combination approaches to CKM therapies, strategies for managing adverse effects, and special considerations for CKD subpopulations where data are more limited. Adoption of a CKM framework in nephrology practice promotes coordinated, multidisciplinary care and provides an opportunity to shift from organ-specific management toward a more holistic approach aimed at reducing cardiovascular events, slowing kidney disease progression, and improving patient-centered outcomes across the continuum of kidney disease. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2026_09_02_KTS_September2026.mp3.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bansal N, Bjornstad P, Bress AP, et al. ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome. J Am Soc Nephrol. 2026. PMID: 42684397. doi:10.1681/ASN.0000001231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。